BenevolentAI Investor Conference Presentation Deck
Robust pipeline entirely generated by the Benevolent
Platform™
BEN-2293 | Atopic Dermatitis
BEN-8744 | Ulcerative Colitis
BEN-28010 | Glioblastoma Multiforme
BEN-9160 | Amyotrophic Lateral Sclerosis
Inflammatory Bowel Disease
Amyotrophic Lateral Sclerosis
Antiviral
Oncology
Oncology
Parkinson's Disease
Nonalcoholic Steatohepatitis (NASH)
Oncology
Parkinson's Disease
Fibrosis
Inflammation
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Chronic Kidney Disease
+10 Exploratory stage programmes
Target ID
Chemistry &
Lead Opt
AstraZeneca
AstraZeneca
Preclinical
AstraZeneca
27.01.2021
15.12.2021
AstraZeneca 17.05.2022
06.10.2022
AstraZeneca 06.10.2022
Phase I
Phase II
Highlights
• BEN-2293 - Phase Ib complete,
Phase Ila ongoing
• BEN-8744 - Novel target with
zero prior linkage to UC.
Delivered drug candidate
within 2 years from programme
initiation
• All pipeline programmes
generated using the Benevolent
Platform™
Benevolent 18View entire presentation